Clinical trials: Advanced Solid Malignant Tumor
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Solid Tumor
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
- Trial name
- NCT06220318
- Testing
- C019199, Sintilimab
- Where
- 2 sites in China
- Volunteers
- 155 people
- Sponsor
- Fujian Haixi Pharmaceuticals Co., Ltd.
Advanced Solid Tumors
Lapatinib and Bortezomib in Patients With Advanced Malignancies
This study is for patients with an advanced type of cancer for which no curative treatment exists. The purpose of this study is to test the safety and efficacy of the combination of the study drugs, lapatinib and bortezomib.
- Trial name
- NCT01497626
- Testing
- Lapatinib and bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Georgetown University
Solid Tumor
A Study of ASP1012 in Adults With Solid Tumors
ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers. ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone.
- Trial name
- NCT06171178
- Testing
- ASP1012, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Solid Tumor
A Study in Participants With Advanced Solid Tumors
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01682135
- Testing
- Ramucirumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Metastatic Colorectal Cancer
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors.
- Trial name
- XAD (NCT00920868)
- Testing
- dasatinib, bevacizumab, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Herbert Hurwitz, MD
Unspecified Adult Solid Tumor, Protocol Specific
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow…
- Trial name
- NCT00002950
- Testing
- sargramostim, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Solid Tumor, Adult
NeoTIL in Advanced Solid Tumors
Single center, single arm pilot trial to test the feasibility, safety and efficacy of NeoTIL-ACT combined with low-dose irradiation (LDI) in patients with advanced, recurrent or metastatic solid tumors.
- Trial name
- NCT04643574
- Testing
- NeoTIL, Cyclophosphamide, Fludarabine
- Where
- Switzerland
- Volunteers
- 42 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Advanced Solid Tumor
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .
- Trial name
- NCT05142423
- Testing
- AK109+AK104
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Akeso
Cancer, Lymphoma
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous…
- Trial name
- NCT00526838
- Testing
- XL228
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Exelixis
Unspecified Adult Solid Tumor, Protocol Specific
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006485
- Testing
- alvocidib, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
- Trial name
- FIRST (NCT05525559)
- Testing
- ET0038
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
Solid Tumor
Clinical Study of KD6001 in Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.
- Trial name
- NCT05230290
- Testing
- KD6001 Injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
Advanced Solid Tumor
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib).
- Trial name
- NCT06497010
- Testing
- Biological: PD-1, Biological: InnoPCV
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital Of Guizhou Medical University
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Advanced Malignant Solid Tumor
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors.
- Trial name
- NCT04165590
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific, Cancer
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.
- Trial name
- COBRA (NCT00849550)
- Testing
- capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Herbert Hurwitz
Solid Tumor, Cancer
DXP-106 in Solid Tumor Patients.
The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are: For Part I: 1.
- Trial name
- DXP-106 (NCT07532018)
- Testing
- DXP-106
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- Singlomics Biopharmaceuticals Zhuhai Co., Ltd.